Sugi Predict

Sugi Predict / Compounds / SCHEMBL2298971

SCHEMBL2298971

SCHEMBL2298971

Cc1ccc(S(=O)(=O)OC2CN(C(=O)OC(C)(C)C)C2)cc1

nearest known ligand 0.49

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 2/20 0.49
▸ GPR119 Q8TDV5 7/20 0.47
▸ MMP13 P45452 1/20 0.47
▸ KMT2A Q03164 2/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ CYP1A2 P05177 1/20 0.44
▸ STS P08842 3/20 0.42
▸ P2RX7 Q99572 2/20 0.42
▸ TP53 P04637 1/20 0.42
▸ HSD11B1 P28845 1/20 0.41
▸ MMP1 P03956 1/20 0.41
▸ MMP3 P08254 1/20 0.41
▸ MMP7 P09237 1/20 0.41
▸ MMP9 P14780 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25235454 0.91 CYP2D6 (0.44) CYP2D6GPR119MMP13KMT2AMEN1
SCHEMBL221064 0.90 CYP2D6 (0.54) CYP2D6GPR119MMP13KMT2AMEN1
SCHEMBL221063 0.90 CYP2D6 (0.54) CYP2D6GPR119MMP13KMT2AMEN1
SCHEMBL30301990 0.90 NR1H2 (0.47) CYP2D6GPR119MMP13KMT2AMEN1
SCHEMBL222877 0.90 CYP2D6 (0.54) CYP2D6GPR119MMP13KMT2AMEN1
SCHEMBL31506318 0.90 CYP2D6 (0.50) CYP2D6GPR119MMP13KMT2AMEN1
SCHEMBL771264 0.88 CYP2D6 (0.49) CYP2D6GPR119MMP13KMT2AMEN1
SCHEMBL15472723 0.88 CYP2D6 (0.49) CYP2D6GPR119MMP13KMT2AMEN1
SCHEMBL17181765 0.88 CYP2D6 (0.49) CYP2D6GPR119MMP13KMT2AMEN1
SCHEMBL2412974 0.88 RORC (0.46) GPR119STS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026102212-A1 MACROCYCLIC MCL-1 INHIBITORS VANDERBILT UNIVERSITY (US) 2026-05-15 — — WO disclosed
US-12559454-B2 Benzenesulfonamide derivatives and uses thereof 2692372 ONTARIO, INC. (CA) 2026-02-24 — — US disclosed
US-12552775-B2 Compounds and uses thereof FOGHORN THERAPEUTICS INC. (US) 2026-02-17 — — US disclosed
US-12391686-B2 Compounds and uses thereof FOGHORN THERAPEUTICS INC. (US) 2025-08-19 — — US disclosed
EP-4262808-B1 FUSED BICYCLIC PYRAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES MERCK SHARP & DOHME LLC (US) 2025-08-13 — — EP disclosed
EP-4592286-A1 MACROCYCLIC NITROGEN-CONTAINING CROWN ETHER COMPOUND AND USE THEREOF AS PROTEIN KINASE INHIBITOR Artivila Biopharma (CN) 2025-07-30 — — EP disclosed
US-20250115598-A1 BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2025-04-10 — — US disclosed
US-20250059176-A1 SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER GUANGZHOU INNOCARE PHARMA TECH CO LTD (CN) 2025-02-20 — — US disclosed
US-20250059188-A1 ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2025-02-20 — — US disclosed
EP-4501327-A2 SUBSTITUTED PYRROLOPYRIMIDINE AND PYRAZOLOPYRIMIDINE AS BRUTON S TYROSINEKINASE (BTK) DEGRADERS Accutar Biotechnology Inc. (US) 2025-02-05 — — EP disclosed
US-20130131035-A1 CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS AMGEN INC. (US) 2013-05-23 — — US disclosed
EP-2536689-A1 ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN Amgen Inc. (US) 2012-12-26 — — EP disclosed
WO-2012170752-A1 NOVEL COMPOUNDS GLAXO WELLCOME MANUFACTURING PTE LTD (SG) 2012-12-13 — — WO disclosed
WO-2012170752-A1 NOVEL COMPOUNDS GLAXO WELLCOME MANUFACTURING PTE LTD (SG) 2012-12-13 — — WO disclosed
WO-2011103196-A1 ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN AMGEN INC. (US) 2011-08-25 — — WO disclosed
US-7842688-B2 Organic compounds NOVARTIS PHARMA AG (CH) 2010-11-30 — — US disclosed
US-20090012055-A1 Organic compounds HEROLD PETER 2009-01-08 — — US disclosed
EP-1961752-A2 Piperidine Compounds Speedel Experimenta AG (CH) 2008-08-27 — — EP disclosed
EP-1670760-A1 ORGANIC COMPOUNDS Speedel Experimenta AG (CH) 2006-06-21 — — EP disclosed
WO-2005061457-A1 ORGANIC COMPOUNDS SPEEDEL EXPERIMENTA AG (CH) 2005-07-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12552775-B2 Compounds and uses thereof SMARCC1, SMARCC2, CHD1 CYP2D6 3648/4885GPR119 1314/4885MMP13 4160/4885
US-20090012055-A1 Organic compounds REN, ACE, ACE2 CYP2D6 46/4885GPR119 729/4885MMP13 2145/4885
US-20250115598-A1 BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS MLKL, CASP1, CASP9 CYP2D6 1102/4885GPR119 2316/4885MMP13 2222/4885
US-20250059176-A1 SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER BTK, SYK, LYN CYP2D6 3201/4885GPR119 1115/4885MMP13 4701/4885
US-12391686-B2 Compounds and uses thereof VHL, TFEB, BECN1 CYP2D6 3885/4885GPR119 3031/4885MMP13 4213/4885
US-12559454-B2 Benzenesulfonamide derivatives and uses thereof NR2E1, NR2C2, NR3C1 CYP2D6 2561/4885GPR119 719/4885MMP13 3226/4885
US-20130131035-A1 CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS CACNA1B, SCN1A, CACNA1I CYP2D6 2398/4885GPR119 1331/4885MMP13 4116/4885
US-20250059188-A1 ARYLSULPHONAMIDE COMPOUNDS MLKL, CASP1, CASP9 CYP2D6 1472/4885GPR119 1420/4885MMP13 3172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.